Home › Funds › TANG CAPITAL MANAGEMENT LLC › SYRE

TANG CAPITAL MANAGEMENT LLC position in SYRE

SPYRE THERAPEUTICS INC · Health Care

TANG CAPITAL MANAGEMENT LLC reported holding 1,892,200 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$168.5M, representing 7.75% of its reported portfolio and ranking #4 among its reported holdings. TANG CAPITAL MANAGEMENT LLC has disclosed SYRE holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

Latest position (Q3 2026)1.89M sh
Reported value held$168.46M
Portfolio Weight7.75%
First reportedQ1 2025
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How TANG CAPITAL MANAGEMENT LLC's SYRE position evolved

TANG CAPITAL MANAGEMENT LLC first disclosed a stake in SYRE in Q1 2025 at 2,050,000 shares (US$33.1M). The position peaked in Q3 2026 at 1,892,200 shares, worth US$168.5M. Across 7 filings, TANG CAPITAL MANAGEMENT LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 1,892,200 shares valued at US$168.5M. Notable position changes include a 56% increase in Q2 2025 (shares rose 12% over the following quarter), a 41% trim in Q4 2025 (shares rose 54% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2025 2.05M $33.08M New
Q2 2025 3.20M $47.90M Add
Q3 2025 3.20M $53.63M Hold
Q4 2025 1.89M $61.99M Reduce
Q1 2026 1.89M $95.44M Hold
Q2 2026 1.89M $167.99M Hold
Q3 2026 1.89M $168.46M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 68 other funds we track also report a position in SYRE — the largest reported positions include Paradigm Biocapital Advisors LP (US$396.8M), RTW INVESTMENTS, LP (US$328.7M), PERCEPTIVE ADVISORS LLC (US$309.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has TANG CAPITAL MANAGEMENT LLC held SYRE?

TANG CAPITAL MANAGEMENT LLC has disclosed SYRE holdings in 7 of the last 7 reported quarters, going back to Q1 2025.

What is TANG CAPITAL MANAGEMENT LLC's current position in SYRE?

As of Q3 2026, TANG CAPITAL MANAGEMENT LLC holds 1.89M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $168.46M, representing 7.75% of its reported portfolio and ranking #4.

Has TANG CAPITAL MANAGEMENT LLC been buying or selling SYRE?

In the latest 13F filing (Q3 2026), TANG CAPITAL MANAGEMENT LLC held unchanged its position in SYRE. The position peaked in Q3 2026 at 1.89M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include Paradigm Biocapital Advisors LP, RTW INVESTMENTS, LP, PERCEPTIVE ADVISORS LLC, among 68 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.